23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of 23andMe Holding Co.. 23andMe Holding Co. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of 23andMe Holding Co. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of 23andMe Holding Co. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of 23andMe Holding Co. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of 23andMe Holding Co. and all latest updates of the company are provided. The 2025 version of 23andMe Holding Co. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.
